3-(1-methyl-1H-1,2,4-triazol-3-yl)pyridine | 120241-69-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(1-methyl-1H-1,2,4-triazol-3-yl)pyridine
• 英文别名: 3-(1-methyl-1H-[1,2,4]triazol-3-yl)-pyridine；1-Methyl-3-(pyridin-3-yl)-1,2,4-triazole；1-Methyl-3-(3-pyridyl)-1,2,4-triazole；3-β-Pyridyl-1-methyl-1,2,4-triazol；3-(1-methyl-1,2,4-triazol-3-yl)pyridine
• CAS: 120241-69-2
• 化学式: C₈H₈N₄
• 分子量: 160.178
• InChiKey: URJODGBKIRDBSY-UHFFFAOYSA-N

物化性质

• 熔点：
  58-60 °C(Solv: ethyl ether (60-29-7))
• 沸点：
  353.8±44.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(1-methyl-1H-1,2,4-triazol-3-yl)pyridine 、 7β-<2-(2-aminothiazol-4yl)-2-(Z)-methoximinoacetamide>-3-iodomethyl-2-<(trimethylsilyloxy)carbonyl>cephalosporin 以 乙腈 为溶剂， 生成 (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[3-(1-methyl-1,2,4-triazol-3-yl)pyridin-1-ium-1-yl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
  参考文献：
  名称：

  New Cephalosporin Antibiotics with 3-Triazolylpyridiniummethyl Substituents.

  摘要：

  DOI：

  10.7164/antibiotics.54.460
• 作为产物：
  描述：

  N-dimethylaminomethylene-nicotinamide 在 sodium hydride 、 一水合肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 3-(1-methyl-1H-1,2,4-triazol-3-yl)pyridine
  参考文献：
  名称：

  1-甲基-5-（吡唑-3-和-5-基-和1, 2, 4-三唑-3-和5-基）-1, 2, 3, 6-四氢吡啶衍生物的合成及其作为毒蕈碱受体配体

  摘要：

  一系列1-甲基-5-（吡唑-3-和-5-基-和1、2、4-三唑-3-和5-基）-1、2、3、6-四氢吡啶衍生物使用 [3H] 哌仑西平和 [3H] NMS 作为配体，合成并在 M1、M2 和 M3 毒蕈碱受体上评估槟榔碱。结合亲和力取决于替代物的位置和大小。在离体器官和体内胆碱能副作用的功能研究中进一步评估了最有趣的化合物。化合物5l和6i在体外具有良好的M1和M3拮抗特性并且在体内没有胆碱能副作用。

  DOI：

  10.1002/ardp.200390013

文献信息

• 1,2,3-Triazole and tetrazole substituted piperidine or
  申请人：H. Lundbeck A/S

  公开号：US04866077A1

  公开（公告）日：1989-09-12

  The present invention relates to novel compounds of the following formula, where the dotted line designates an optional bond: ##STR1## wherein "het" designates a five membered heterocyclic ring which may include 1 or 2 double bonds and 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, provided that "het" may not designate a 1,2,4- or 1,3,4-oxadiazole; R.sup.1 is selected from hydrogen, lower alkyl, optionally substituted with phenyl which may be substituted with halogen, lower alkyl, or lower alkoxy, or a group R.sup.6 --CO--NH--CH.sub.2 -- or R.sup.6 --O--CO--, wherein R.sup.6 is lower alkyl, branched or unbranched, or phenyl optionally substituted with halogen, trifluoromethyl, lower alkyl, hydroxy, lower alkoxy, or lower acyloxy; R.sup.2 and R.sup.3 are the same or different, each representing hydrogen, lower alkyl, cycloalkyl (3-6 C-atoms), lower alkenyl, lower alkadienyl, lower alkynyl, optionally substituted with hydroxy, halogen or phenyl, in which the phenyl group may be substituted with halogen, trifluoromethyl, lower alkyl, hydroxy or lower alkoxy; R.sup.2 and R.sup.3 may further, respectively, be selected from trifluoromethyl or phenyl optionally substituted with halogen, trifluoromethyl, lower alkyl, hydroxy, lower alkoxy or lower acyloxy, or R.sup.2 and R.sup.3 may, respectively, be a group OR.sup.7 or SR.sup.7 wherein R.sup.7 is defined as R.sup.2 or R.sup.3, and if "het" includes 2 or more carbon atoms, R.sup.4 and R.sup.5 are the same or different, and each is defined as R.sup.2 or R.sup.3, and if "het" includes only one carbon atom, there is only one substituent, R.sup.4, on the heterocyclic ring, and R.sup.4 is defined as R.sup.2 or R.sup.3, as well as individual stereo isomers and pharmaceutically acceptable acid addition salts thereof. The invention moreover relates to methods for the preparation of the compounds of formula I, to novel intermediates, to pharmaceutical compositions containing same and to methods for the treatment of disorders, caused by malfunction of the acetylcholine (AcCh) or muscarinic system, by administering a non-toxic effective amount of a compound of formula I.

  本发明涉及以下式的新化合物，其中虚线表示可选键：##STR1##其中“het”表示一个五元杂环，可能包括1或2个双键和1-4个从氮、氧或硫中选择的杂原子，但“het”不能表示1,2,4-或1,3,4-噁二唑；R.sup.1选择自氢、较低的烷基，可选地取代为苯基，苯基可能被卤素、较低的烷基或较低的烷氧基取代，或者是一个基团R.sup.6--CO--NH--CH.sub.2--或R.sup.6--O--CO--，其中R.sup.6是较低的烷基、支链或直链，或者是可选地取代为卤素、三氟甲基、较低的烷基、羟基、较低的烷氧基或较低的酰氧基的苯基；R.sup.2和R.sup.3相同或不同，各自代表氢、较低的烷基、环烷基（3-6个碳原子）、较低的烯基、较低的烷二烯基、较低的炔基，可选地取代为羟基、卤素或苯基，其中苯基可能被卤素、三氟甲基、较低的烷基、羟基或较低的烷氧基取代；R.sup.2和R.sup.3还可以分别选择三氟甲基或可选地取代为卤素、三氟甲基、较低的烷基、羟基、较低的烷氧基或较低的酰氧基的苯基，或者R.sup.2和R.sup.3可以分别是一个基团OR.sup.7或SR.sup.7，其中R.sup.7定义为R.sup.2或R.sup.3，如果“het”包括2个或更多个碳原子，则R.sup.4和R.sup.5相同或不同，各自定义为R.sup.2或R.sup.3，如果“het”只包括一个碳原子，则在杂环上只有一个取代基R.sup.4，R.sup.4定义为R.sup.2或R.sup.3，以及其单独的立体异构体和药学上可接受的酸盐。此外，本发明还涉及制备式I化合物的方法，新的中间体，含有相同化合物的药物组合物，以及通过给予式I化合物的非毒性有效量来治疗由乙酰胆碱（AcCh）或肌碱系统功能障碍引起的疾病的方法。
• Oxazole and thiazole derivatives and their use for treating disorders
  申请人：H. Lundbeck A/S

  公开号：US04925858A1

  公开（公告）日：1990-05-15

  The present invention relates to novel compounds of the following formula, where the dotted line designates an optional bond: ##STR1## wherein "het" designates a five membered heterocyclic ring which may include 1 or 2 double bonds and 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, provided that "het" may not designate a 1,2,4- or 1,3,4-oxadiazole; R.sup.1 -R.sup.5 are as defined in the specification; as well as individual stereo isomers and pharmaceutically acceptable acid addition salts thereof. The invention moreover relates to methods for the preparation of the compounds of formula I, to novel intermediates, to pharmaceutical compositions containing same and to methods for the treatment of disorders, caused by malfunction of the acetylcholine (AcCh) or muscarinic system, by administering a non-toxic effective amount of a compound of formula I.

  本发明涉及以下式子的新化合物，其中点线表示可选键：##STR1## 其中“het”表示一个五元杂环环，可以包括1或2个双键和1-4个从氮、氧或硫中选择的杂原子，但“het”不能表示1,2,4-或1,3,4-噁二唑；R.sup.1-R.sup.5如规范中所定义；以及其个别立体异构体和药学上可接受的酸加成盐。此外，本发明还涉及制备式I化合物的方法、新的中间体、包含其的药物组合物以及通过给予式I化合物的非毒性有效量治疗因乙酰胆碱（AcCh）或肌动系统功能障碍而引起的疾病的方法。
• 1,2,3-triazole and tetrazole substituted piperidine or
  申请人：H. Lundbeck, A/S

  公开号：USRE036374E1

  公开（公告）日：1999-11-02

  The present invention relates to novel compounds of the following formula, where the dotted line designates in optional bond: ##STR1## wherein "het" designates a five membered heterocyclic ring which may include 1 or 2 double bonds and 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, provided that "het" may not designate a 1,4- or 1,3,4-oxadiazole, R.sup.1 is selected from hydrogen, lower alkyl, optionally substituted with phenyl which may be substituted with halogen, lower alkyl, or lower alkoxy, or a group R.sup.6 --CO--NH--CH.sub.2 -- or R.sup.6 --O--CO--, wherein R.sup.6 is lower alkyl, branched or unbranched, or phenyl optionally substituted with halogen, trifuoromethyl, lower alkyl, hydroxy, lower alkoxy, or lower acyloxy; R.sup.2 and R.sup.3 are the same or different, each representing hydrogen, lower alkyl, cycloalkyl (3-6 C-atoms), lower alkenyl, lower alkadienyl, lower alkynyl, optionally substituted with hydroxy, halogen or phenyl, in which the phenyl group may be substituted with halogen, trifluoromethyl, lower alkyl, hydroxy or lower alkoxy; R.sup.2 and R.sup.3 may further, respectively, be selected from trifluoromethyl or phenyl optionally substituted with halogen, trifluoromethyl, lower alkyl, hydroxy, lower alkoxy or lower acyloxy, or R.sup.2 and R.sup.3 may, respectively, be a group OR.sup.7 or SR.sup.7 wherein R.sup.7 is defined as R.sup.2 or R.sup.3, and if "het" includes 2 or more carbon atoms R.sup.4 and R.sup.5 are the same or different, and each is defined as R.sup.2 or R.sup.3, and if "het" includes only one carbon atom, there is only one substituent, R.sup.4, on the heterocyclic ring, and R.sup.4 is defined as R.sup.2 or R.sup.3, as well as individual stereo isomers and pharmaceutically acceptable acid addition salts thereof. The invention moreover relates to methods for the preparation of the compounds of formula 1, to novel intermediates, to pharmaceutical compositions containing same and to methods for the treatment of disorders, caused by malfunction of the acetylcholine (AcCh) or muscarinic system, by administering a non-toxic effective amount of a compound of formula I.

  本发明涉及以下式的新化合物，其中点线表示可选键：##STR1##其中“het”表示一个五元杂环环，可以包括1或2个双键和1-4个从氮、氧或硫中选择的杂原子，前提是“het”不能表示1,4-或1,3,4-噁二唑，R.sup.1选择自氢、较低的烷基，可选地取代为苯基，苯基可以取代为卤素、较低的烷基或较低的烷氧基，或者是一个R.sup.6 -CO-NH-CH.sub.2-或R.sup.6-O-CO-基团，其中R.sup.6是较低的烷基，分支或非分支，或苯环，可选地取代为卤素、三氟甲基、较低的烷基、羟基、较低的烷氧基或较低的酰氧基；R.sup.2和R.sup.3相同或不同，每个表示氢、较低的烷基、环烷基（3-6个碳原子）、较低的烯基、较低的烷二烯基、较低的炔基，可选地取代为羟基、卤素或苯基，在其中苯基可以取代为卤素、三氟甲基、较低的烷基、羟基或较低的烷氧基；R.sup.2和R.sup.3可以进一步分别选择三氟甲基或苯基，可选地取代为卤素、三氟甲基、较低的烷基、羟基、较低的烷氧基或较低的酰氧基，或R.sup.2和R.sup.3可以分别是OR.sup.7或SR.sup.7基团，其中R.sup.7定义为R.sup.2或R.sup.3，如果“het”包括2个或多个碳原子，则R.sup.4和R.sup.5相同或不同，每个定义为R.sup.2或R.sup.3，如果“het”仅包括一个碳原子，则杂环环上只有一个取代基R.sup.4，定义为R.sup.2或R.sup.3，以及其个别立体异构体和药学上可接受的酸加合物。此外，本发明还涉及制备公式1化合物的方法、新的中间体、含有同样化合物的制药组合物以及通过给予公式I化合物的非毒性有效量治疗由乙酰胆碱（AcCh）或肌动系统功能不良引起的疾病的方法。
• Heterocyclic compounds
  申请人：H. LUNDBECK A/S

  公开号：EP0296721B1

  公开（公告）日：1993-06-23
• MACROLIDES WITH ANTIBACTERIAL ACTIVITY
  申请人：Basilea Pharmaceutica AG

  公开号：EP1478653B1

  公开（公告）日：2014-07-02